Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use

References

• Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization. M4WR48(RR-12) (1999).
   Google Scholar
• •• Updates the ACIP's 1996 recommendations on the prevention of hepatitis A through immunization and includes new data on epidemiology of the disease and effectiveness of vaccination programs.
   Google Scholar
• Leentvaar-Kuijpers A, Coutinho RA, Brulein V, Safary A. Simultaneous passive and active immunization against hepatitis A. Vaccine 10 (Suppl. 1), 5138–5141 (1992).
   Google Scholar
• Zaaijer A, Leentvaar-Kuijpers A, Rotman H, Lelie PN. Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization. J. Med. Viral. 40,22–27 (1993).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis A vaccines WHO position paper. Weekly Epidemiology Recon175, 38–44 (2000).
   Google Scholar
• Berge JJ, Drennan DP, Jacobs RJ et al The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatol 31,469–473 (2000).
   PubMed Web of Science ®Google Scholar
• Van Damme P, Bell B. Meeting report. Hepatitis A: how to match prevention strategies to changing epidemiology. Vaccine 19,999–1002 (2001).
   Google Scholar
• Banatvala J. Epidemiology of hepatitis A (HAV) in Europe and its relationship to immunisation. In: Proceedings of the International Symposium on enterically-transmitted hepatitis viruses. Buisson Y, Coursaget P, Kane M (Eds.), La Simarre, Tours, France 72–77 (1996).
   Google Scholar
• ••Full review of hepatitis A epidemiology inEtuppe.
   Google Scholar
• Maguire HC, Handford S, Perry KR et al A collaborative case control study of sporadic hepatitis A in England. Communicable Disease Report 5(3), 33–40 (1995).
   Google Scholar
• Mele A, Sagliocca L, Palumbo F et al Travel-associated hepatitis A: effect of place of residence and country visited. J. Public Health Med 14,342–343 (1992).
   Google Scholar
• Allen CJ, Ferson MJ. Notification of infectious diseases by general practitioners: a quantitative and qualitative study. Med. J. Aust. 172,325–328 (2000).
   PubMedGoogle Scholar
• Rods TH, Christl M, Kazmierczak JJ, WR M, Davis JR Hepatitis A infections in Wisconsin: trends in incidence and factors affecting surveillance, 1986-1995. WNIJ 97,32–38 (1998).
   Google Scholar
• Hadler SC, Webster HM, Erben JJ, Swanson JE, Maynard JE. Hepatitis A in daycare centers: a community-wide assessment. N Engl. Med. 302,1222-1227 (1980).
   Google Scholar
• Smith S, Weber S, Wiblin T, Nettleman M. Cost-effectiveness of hepatitis A vaccination in healthcare workers. Infect. Gantt& Hasp. Epidemiol 18,688–691 (1997).
   PubMedGoogle Scholar
• Rosenblum LS, Villarino ME, Nainan OV et al Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J. Infect. Dis. 164(3), 476–482 (1991).
   Google Scholar
• Centers for Disease Control and Prevention. Hepatitis Surveillance Report. 57,10 (2000).
   Google Scholar
• Bell BP, Shapiro CN, Alter MJ et al The diverse patterns of hepatitis A epidemiology in the United States - implications for vaccination strategies. J. Infect. Dis. 178, 1579–1584 (1998).
   PubMed Web of Science ®Google Scholar
• ••Concise review from the CDC HepatitisBranch, with a pediatric focus.
   Google Scholar
• O'Grady JG. Fulminant hepatitis in patients with chronic liver disease. J. Vital Hepat. 7 (Suppl. 1), 9–10 (2000).
   Google Scholar
• Debray D, Cuilufi P, Devictor D, Fabre M, Bernard O. Liver failure in children with hepatitis A. Hepatol 26,1018–1022 (1997).
   PubMed Web of Science ®Google Scholar
• Ciocca M. Clinical course and consequences of hepatitis A infection. Vaccine 18, s71—s74 (2000).
   Google Scholar
• Garin D, Biziagos E, Crance JM et al. Survival of infectious hepatitis A virus in mineral water and seawater. In: Proceedings of the International Symposium on enterically-transmitted hepatitis viruses. Buisson Y, Coursaget P, Kane M (Eds.), La Simarre, Tours, France 48–49 (1996).
   Google Scholar
• Hutin YJ, Pool V, Cramer EH, Nainan OV, Weth J, Williams IT A multistate, foodborne outbreak of hepatitis A. N Engl J. Med. 340,595–602 (1999).
   PubMedGoogle Scholar
• Staes CJ, Schlenker TL, Risk I et al Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. Pediatrics 106, E54 (2000).
   PubMed Web of Science ®Google Scholar
• Craig AS, Sockwell DC, Schaffner W et al. Use of hepatitis A vaccine in a community-wide outbreak of hepatitis A. Clin. Infect. Dis. 27,531–535 (1998).
   PubMedGoogle Scholar
• Tilzey AJ, Banatvala JE. Hepatitis A. Br. Med.J. 302,1552–1553 (1991).
   Google Scholar
• Barros H, Oliveira F, Miranda H. A survey on hepatitis A in Portuguese children and adolescents. J. ViraL Hepat 6,249–253 (1999).
   PubMedGoogle Scholar
• Stroffolini T, D'Amelio R, Matricardi PM et al. The changing epidemiology of hepatitis A in Italy. Ital. j Gastroenterol 25, 372–374 (1993).
   Google Scholar
• Zanetti AR, Romano L, Tanzi E et al Decline in antiHAV prevalence in the Milan area between 1958 and 1992. Eur. Epidemiol 25,633–635 (1994).
   Google Scholar
• Beutels M, Van Damme P, Vranckx R, Meheus A. The shift in prevalence of hepatitis A immunity in Flanders, Belgium. Acta. Gastroenterol Belg. 61,4–7 (1998).
   PubMedGoogle Scholar
• Polz-Dacewicz MA, Polickiewicz P, Badach Z. Changing epidemiology of hepatitis A virus infection - a comparative study in central eastern Poland. Med Sci. Monit. 6, 989–993 (2000).
   Google Scholar
• Beran J, Douda P, Rychly R. Seroprevalence of viral hepatitis A in the Czech Republic. Eur I Epidemiol 15,805–808 (1999).
   Google Scholar
• Das K, Jain A, Gupta S et al The changing epidemiological pattern of hepatitis A in an urban population of India: emergence of a trend similar to the European countries. Eur I Epidemiol 16,507–510 (2000).
   PubMedGoogle Scholar
• Yap I, Guan R. Hepatitis A seroepidemiology in Singapore: a changing pattern. Trans. Roy Soc. Bop. Med Hyg. 87,22–23 (1993).
   PubMed Web of Science ®Google Scholar
• Kalayanarooj S, Vaughn DW, Snitbhan R, Ariyasriwatana C. Age-specific prevalence of hepatitis A antibody in Thai children. SoutheastAsianj Top. Med Public Health 26,709–711 (1995).
   PubMedGoogle Scholar
• Poovorawan Y, Vimolkej T, Chongsrisawat V, Theamboonlers A, Chumdermpadetsuk S. The declining pattern of seroepidemiology of hepatitis A virus infection among adolescents in Bangkok, Thailand. SoutheastAsianj 7i-op. Med Public Health28, 154–157 (1997).
   Google Scholar
• Sohn YM, Rho HO, Park MS et al The changing epidemiology of hepatitis A in children and the consideration of active immunization in Korea. Yonsei Med 141, 34–39 (2000).
   Google Scholar
• André FE. Hepatitis A vaccine: current status and future use. In: Proc IX Triennia] International Symposium on Viral Hepatitis and Liver Disease. Rizzetto M, Purcell RII,Germn JL, Verme G (Eds.), Minerva Medica, Rome, Itlay, 624–626 (1997).
   Google Scholar
• Werzberger A, Mensch B, Kuter B et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N &iguj Med 327,453–457 (1992).
   PubMed Web of Science ®Google Scholar
• Innis BL, Snitbhan R, Kunasol P et al. Protection against hepatitis A by an inactivated vaccine. 161/11A 271,1328–1334 (1994).
   Google Scholar
• Van Herck K, Beutels P, Van Damme P et al Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines.J Med Viral. 60(1), 1–7 (2000).
   Google Scholar
• André FE. Randomised, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 20,292–293 (2002).
   Google Scholar
• Peetermans J. Production quality control and charaterization of an inactivated hepatitis A vaccine. Vaccine10(1), S99—S101 (1992).
   Google Scholar
• André FE, D'Hondt E, Delem A, Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: Rationale and summary of findings. Vaccine 10(1), S160–5169 (1992).
   Google Scholar
• ••Review of the objectives established at thebeginning of the clinical development program for HAV vaccine and summary of the early findings.
   Google Scholar
• Miller MJ. Summary of current nomenclature, taxonomy and classification of various microbial agents. Clin. Infect. Dis. 16,597–615 (1993).
   Google Scholar
• Stapleton JT, Lemon SM. New vaccines against hepatitis. In: New Generation Vaccines. Levine MM, Woodrow GC, Kaper JB, Cobon GS (Eds.), Marcel Dekker, Inc., New York, USA 571–585 (1997).
   Google Scholar
• Findor JA, Canero Velasco MC, Mutti J, Safary A. Response to hepatitis A vaccine in children after a single dose with a booster administration 6 months later. J. Travel Med 3,156–159 (1996).
   Google Scholar
• Hollinger FB, André FE, Melnick J (Eds.) Proceedings of International Symposium on active immunization against hepatitis A. Vaccine 1, S1—S176 (1992).
   Google Scholar
• Irwin DJ, Millership S. Antibody responses to hepatitis A vaccine in healthy adults. Commun. Dis. Public Health4(2), 139–140 (2001).
   Google Scholar
• Jilg W, Bittner R, Bock HL et al. Vaccination against hepatitis A: comparison of different short-term immunization schedules. Vaccinel0 (Suppl. 1), S126—S128 (1992).
   Google Scholar
• Van Damme P, Mathei C, Thoelen S, Meheus A, Safary A, André FE. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. Med. Viral. 44,435-441 (1994).
   Google Scholar
• •Early trial in healthy volunteers to evaluate the safety and imrnunogenicity of a single dose of 1440 FLU HAV vaccine.
   Google Scholar
• World Health Organization. Public health control of hepatitis A: Memorandum from a WHO meeting. Buff WI-1073(1), 15–20 (1995).
   Google Scholar
• Robertson BH, D'Hondt E, Spelbring J, Tian H, Krawczynski K, Margolis HS. Effect of post-exposure vaccination in a chimpanzee model of hepatitis A virus infection. J. Med. Viral. 43,249–251 (1994).
   PubMedGoogle Scholar
• D'Hondt E, Purcell RII, Emerson SU, Wong DC, Shapiro M, Govindarajan S. Efficacy of an inactivated hepatitis A vaccine in pre- and post-exposure conditions in marmosets. I Infect. Dis. 171\(Suppl. 1), S40—S43 (1995).
   Google Scholar
• Sagliocca L, Amoroso P, Stroffolini T et al. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial. Lancet 353,1136–1139 (1999).
   PubMed Web of Science ®Google Scholar
• Williams J, Bruden D, McMahon B et al. Response to two doses of hepatitis A vaccine administered an average of 27 months apart. Antiviral. Ther. 5 (Suppl. 1), A13 (2000).
   Google Scholar
• Landry P, Tremblay S, Darioli R, Genton B. Inactivated hepatitis A vaccine booster given at least 24 months after the primary dose. Vaccine 19,339–402 (2001).
   Google Scholar
• Iwarson S, Lindh M, Widerström L. Excellent booster response 4–6 years after a single primary dose of an inactivated hepatitis A vaccine. Land. I Infect. Dis. 34, 110–111 (2002).
   Google Scholar
• •Study in 25 travelers of a booster dose of 1440 Ef.1.1 given 4–6 years after the primary dose.
   Google Scholar
• Iwarson S. Are we giving too many doses of hepatitis A and B vaccines? Vaccine In press (2002).
   Google Scholar
• Gil A, Gonzalez A, Dal-Re R, Calero JR. Interference assessment of yellow fever vaccine with the immune response to a single dose of inactivated hepatitis A vaccine (1440 El.U) . A controlled study in adults. Vaccine 14, 1028–1030 (1996).
   Google Scholar
• Van Hoecke C, Lebacq E, Beran J, Prymula R, Collard F. Concomitant vaccination against hepatitis A and typhoid fever. J. Travel Med. 5, 116–120 (1998).
   Google Scholar
• Bock HL, Kruppenbacher JP, Bienzle U, De Clercq NA, Hofmann F, Clemens RL. Does the concurrent administration of an inactivated hepatitis A vaccine influence the immune response to other travellers vaccines?' Pavel Merl 7, 74–78 (2000).
   Google Scholar
• Thoelen S, Van Damme P, Leentvaar-Kuijpers A et al The first combined vaccine against hepatitis A and B: an overview. Vaccine 17, 1657–1662 (1999).
   PubMed Web of Science ®Google Scholar
• Joines RVV, Blotter M, Abraham B et al A prospective, randomised, comparative US trial of a combination hepatitis A and B vaccine (Twinrie) with corresponding monovalent vaccines (Havrix® and Engerix-B°) in adults. Vaccine 19, 4710–4719 (2001).
   PubMed Web of Science ®Google Scholar
• Briem H, Safary A. Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later. J. Merl Viral. 44, 443–445 (1994).
   Google Scholar
• Keeffe EB, Iwarson S, McMahon BJ et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatol 27(3), 881–886 (1998).
   Google Scholar
• •Comparative study in over 250 patients with chronic hepatitis A, B or other chronic liver disease to evaluate the safety and efficacy of HAV vaccine.
   Google Scholar
• Fan PC, Chang MET, Lee PI, Safary A, Lee CY. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine 16, 232–235 (1998).
   Google Scholar
• Kanra G, Yalcin SS, Ceyhan M, Yurdakok K. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children. Turk.j Perliati: 42, 105–108 (2000).
   Google Scholar
• Piazza M, Safary A, Vegnente A et al Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme. Vaccine 17, 585–588 (1999).
   PubMed Web of Science ®Google Scholar
• Dagan R, Amir J, Mijalovsky A et al Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. PediatE Infect. Dicj 19, 1045–1052 (2000).
   PubMed Web of Science ®Google Scholar
• Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men. j Infect. Dis. 176, 1064–1067 (1997).
   Google Scholar
• Tilzey AJ, Palmer SJ, Harrington C, ODoherty MJ. Hepatitis A vaccine responses in HIV-positive persons with haemophilia. Vaccine 14, 1039–1041 (1996).
   Google Scholar
• Chan CY, Lee SD, Yu MI, Wang YJ, Chang FY, Lo KJ. Long-term follow-up of hepatitis A vaccination in children. Vaccine 17, 369–372 (1999).
   Google Scholar
• Lee SD. Hepatitis A vaccination in patients with chronic liver disease in Taiwan. Viral Hepatitis 7 (Suppl. 1), 19–21 (2000).
   Google Scholar
• Stark K, Gunther M, Neuhaus R et al Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. Infect. Dir. 180(6), 2014–2017 (1999).
   PubMed Web of Science ®Google Scholar
• Gunther M, Stark K, Neuhaus R, Reinke P, Schroder K, Bienzle U. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation 71, 477–479 (2001).
   PubMed Web of Science ®Google Scholar
• Riedemann S, Reinhardt G, Frosner GG et al Placebo-controlled efficacy study of hepatitis A vaccine in Valdivia, Chile. Vaccine 10\(Suppl. 1), S152—S155 (1992).
   Google Scholar
• Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. j Merl Viral. 63(1), 1–7 (2001).
   Google Scholar
• •Prediction of the long term persistence of anti-HAV antibodies using mathematical models.
   Google Scholar
• Van Herck K, Van Dame P, Nguyen C. Long-term immunogenicity and safety of an inactivated hepatitis A vaccine. Proc. 10th Int. Cong. Inf. Dis. Singapore, 183, (2002).
   Google Scholar
• Fiore AE, Shapiro CN, Sabin K et al. Persistence of protective antibody levels among children vaccinated during infancy with hepatitis A vaccine differs according to maternal antibody status. Antiviral Ther. 5\(Suppl. 1), 9 (2000).
   Google Scholar
• Cederna JB, Klinzmann D, Stapleton JT. Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine. Vaccine 18, 892–898 (2000).
   Google Scholar
• •Study evaluating the proliferative T-cell responses elicited by HAV vaccine.
   Google Scholar
• Desombere I, van Herck K, van Damme P, Thoelen S, Collard F, Leroux-Roels G. Long-term persistence of cellular immunity towards hepatitis A vaccine (HAV) following HAV vaccination. Antiviral Ther. 5\(Suppl. 1), 7 (2000).
   Google Scholar
• Böttiger M. Long-term immunity following vaccination with killed poliovirus vaccine in Sweden, a country with no circulating poliovirus. Rev Infect. Dis. 6\(Suppl. 2), S548—S551 (1984).
   Google Scholar
• Böttiger M. The elimination of polio in the Scandinavian countries. Public Health Rev 21 (1-2), 27–33 (1994).
   Google Scholar
• Shaw FE, Sudman JH, Smith SM et al A community-wide epidemic of hepatitis A in Ohio. Am. j Epirlemiol 123, 1057–1065 (1986).
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Beller M, Williams J, Schloss M, Tanttila H, Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch. Perliab: Arlolesc. Merl 150, 733–739 (1996).
   Google Scholar
• Prikazsky V, Olear V, Cernoch A, Safary A, André FE. Interruption of an outbreak of hepatitis A in two villages by vaccination. Merl Viral. 44, 457–459 (1994).
   Google Scholar
• Kaic B, Borcic B, Ljubicic M, Brkic I, Mihaljevic I. A control in a refugee camp by active immunization. Vaccine 19, 3615–3619 (2001).
   Google Scholar
• Irwin DJ, Millership S. Control of a community hepatitis A outbreak using hepatitis A vaccine. Commun. Dis. Public Health 2 (3), 184–187 (1999).
   Google Scholar
• Bonanni P, Colombai R, Franchi G, Lo Nostro A, Comodo N, liscione E. Experience of hepatitis A vaccination during an outbreak in a nursery school of Tuscany, Italy. 43irlerniol. Infect. 121(1), 377–380 (1998).
   Google Scholar
• Viral Hepatitis Prevention Board. Hepatitis A: Disease and epidemiology. Hepatitis A update. Viral Hepatitis6, 5–14 (1997). Comprehensive review of hepatitis A.
   Google Scholar
• Steffen R, Kane MA, Shapiro CN, Billo N, Schoellhorn KJ, Van Damme Epidemiology and prevention of hepatitis A in travellers. JAMA 272, 885–889 (1994).
   PubMed Web of Science ®Google Scholar
• Steffen R. Risk of hepatitis A in travellers. Vaccine 10\(Suppl. 1), S69—S70 (1992).
   Google Scholar
• Lee SD, Chan CY, Yu MI, Wang YJ, Lo KJ, Safary A. Single dose-inactivated hepatitis A vaccination schedule for susceptible youngsters. AM. I Gastroenterol 91, 1360–1362 (1996).
   Google Scholar
• European Community. Council Directive 93/88/EEC of 12 October 1993 amending Directive 90/679/EEC on the Protection of workers from risks related to exposure to biological agents at work (seventh individual Directive within the meaning of Article 16 (1) of Directive 89/391/EEC). Official JournalL268, 0071–0082 (1993).
   Google Scholar
• Keefe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am. J. Gastroenterol 90, 201–205 (1995).
   Google Scholar
• Williams I, Bell B, Kaluba J, Shapiro C. Association between chronic liver disease and death from hepatitis A, United States, 1989–92. IX Triennial Int. Symp. Vim' Hepatitis Liver Dis. (1996).
   Google Scholar
• Datta D, Williams I, Culver D, Bloom SC, Bell BR Association between deaths due to hepatitis A and chronic liver disease, United States, 1981–97. 10th Int. Symp. Viral Hepatitis Liver Dis. Atlanta, USA (2000).
   Google Scholar
• Vento S, Garofano T, Renzini C et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl. J. Med. 338(5), 286–290 (1998).
   Google Scholar
• Yao G. Clinical spectrum and natural history of viral hepatitis A in a 1988 Shanghai epidemic. In: Vital Hepatitis and Liver Disease. Williams and Wilkins, Baltimore, USA 76–78 (1991).
   Google Scholar
• Tsang SWC, Sung JJY. Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection. Aliment. Pharmacol Ther. 13, 1445–1449 (1998).
   Google Scholar
• Nebbia G, Giacchino R, Soncini R, Ramaccioni V, Timitilli A, Zanetti AR. Hepatitis A vaccination in chronic carriers of hepatitis B virus. J. Perliatr. 134, 784–785 (1999).
   Google Scholar
• Mannucci PM, Gdovin S, Gringeri A et al. Transmission of hepatitis A to patients with hemophilia by Factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann. Intern. Med. 120, 1–7 (1994).
   PubMed Web of Science ®Google Scholar
• Chudy M, Budek I, Keller-Stanislawski B et al A new cluster of hepatitis A infection in haemophiliacs traced to a contaminated plasma pool. I Med. Vim!. 57, 91–99 (1999).
   PubMed Web of Science ®Google Scholar
• Department of Health, Welsh Office, Scottish Office Department of Health, DHSS (Northern Ireland). Hepatitis A. In: Immunisation against infectious Disease. Salisbury DM, Begg NT (Eds.) HMSO Publications Centre, London, UK, 85–94 (1996).
   Google Scholar
• Viral Hepatitis Prevention Board. Current recommendations on HAV control in selected countries in Europe. Vital Hepatitis 8(16) (1999).
   Google Scholar
• Jacques P, Moens G, Van Damme P et al. Increased risk for hepatitis A among female day nursery workers in Belgium. Occup. Med. (Lond.). 44, 259–261 (1994).
   Google Scholar
• Jensenius M, Ringertz SH, Berild D, Bell H, Espinoza R, Grinde B. Prolonged nosocomial outbreak of hepatitis A arising from an alcoholic with pneumonia. Land. Infect. Dir. 30, 119–123 (1998).
   Google Scholar
• Borg MA, Portelli A. Hospital laundry workers - an at-risk group for hepatitis A? Occup. Med. (Lond). 49, 448–450 (1999).
   Google Scholar
• Weldon M, Van Egdom MJ, Hendricks KA, Regner G, Bell BP, Schulster LM. Prevalence of antibody to hepatitis A virus in drinking water workers and waste water workers in Texas from 1996 to 1997.1 Occup. Environ. Med. 42, 821–826 (2000).
   Google Scholar
• De Serres G, Laliberte D. Hepatitis A among workers from a waste water treatment plant during a small community outbreak. Occup. Envimn. Med. 54, 60–62 (1997).
   PubMed Web of Science ®Google Scholar
• Katz MH, Hsu L, Wong E, Liska S, Anderson L, Janssen RS. Seroprevalence of and risk factors for hepatitis A infection among young homosexual and bi-sexual men. Infect. Dis. 175, 1225–1229 (1997).
   Google Scholar
• Ferson MJ, Young LC, Stokes ML. Changing epidemiology of hepatitis A in the 1990s in Sydney, Australia. Epidemiol Infect. 121, 631–636 (1998).
   Google Scholar
• Villano SA, Nelson KE, Vlahov D, Purcell RH, Saah AJ, Thomas DL. Hepatitis A among homosexual men and injection drug users: more evidence for vaccination. Gun. Infect. Dis. 25, 726–728 (1997).
   PubMed Web of Science ®Google Scholar
• Allard R, Beauchemin J, Bedard L, Dion R, Tremblay M, Carsley J. Hepatitis A vaccination during an outbreak among gay men in Montreal, Canada, 1995–1997. 43idemid. Comm. Health 55, 252–256 (2001).
   Google Scholar
• Bodsworth NJ, Neilsen GA, Donovan B. The effect of immunization with inactivated hepatitis A vaccine on the clinical course of HIV-1 infection: 1-year follow-up. AIDS11, 747–749 (1997).
   Google Scholar
• Anon. Catalonia, Spain introduces mass hepatitis A vaccination programme. Vim' Hepatitis 8, 3–4 (1999).
   Google Scholar
• Lopalco PL, Salleras L, Barbuti S et al. Hepatitis A and B in children and adolescents - what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine 19, 470–474 (2001).
   Google Scholar
• •Account of two European outbreaks and lessons learned from their containment.
   Google Scholar
• Rajan E, Shattock AG, Fielding JF. Cost-effective analysis of hepatitis A prevention in Ireland. Am. J. Gastroenterol 95, 223–226 (2000).
   Google Scholar
• Das A. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries. Hepatol. 29, 548–552 (1999).
   PubMed Web of Science ®Google Scholar
• Shapiro C, Arcari C, Mast E et al. An economic analysis of the use of hepatitis A vaccine to control community-wide epidemics. IX Triennial Int. Symp. Vim' Hepatitis Liver Dis., Rome, Italy (1996).
   Google Scholar
• O'Connor JB, Imperiale TF, Singer ME. Cost-effectiveness analysis of hepatitis A vaccination strategies for adults. Hepatol 30, 1077–1081 (1999).
   PubMed Web of Science ®Google Scholar
• Beutels P, Mast E, Pechevis M et al Economic evaluation of vaccination programmes: A consensus statement focusing on viral hepatitis. PhatmacoEconomic520(1), 1–7 (2002).
   Google Scholar
• ••Interpretation of the evidence provided byeconomic evaluation applied to viral hepatitis vaccination.
   Google Scholar
• Van Doorslaer E, Tormans G, Van Damme P Cost-effectiveness analysis of vaccination against hepatitis A in travellers. j Med. Viral. 44,463–469 (1994).
   PubMed Web of Science ®Google Scholar
• Tormans G, Van Damme P, Van Doorslaer E. Cost-effectiveness analysis of hepatitis A prevention in travellers. Vaccine 10 (Suppl. 1), S88—S92 (1992).
   Google Scholar
• Buma AH, Beutels P, Van Damme P, Tormans G, Van Doorslaer E, Leentvaar-Kuijpers A. An economic evaluation of hepatitis A vaccination in Dutch military personnel. MI. Med. 163,564–567 (1998).
   Google Scholar
• De Juanes JR, Gonzalez A, Arrazola MP, San-Martin M. Cost analysis of two strategies for hepatitis A vaccination of hospital healthcare personnel in an intermediate endemicity area. Vaccine 19, 4130–4134 (2001).
   Google Scholar
• Jacobs RJ, Grover SF, Meyerhoff AS, Paivanna TA. Cost-effectiveness of vaccinating food service workers against hepatitis A infection. Food Prot. 63,768–774 (2000).
   PubMed Web of Science ®Google Scholar
• Meltzer MI, Shapiro CN, Mast EE, Arcari C. The economics of vaccinating restaurant workers against hepatitis A. Vaccine 19, 2138–2145 (2001).
   PubMed Web of Science ®Google Scholar
• Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, André FE. Clinical experience with an inactivated hepatitis A vaccine. Infect. Dis. 171\(Suppl. 1), S44—S49 (1995).
   Google Scholar
• •Summary of clinical results with the 1440 El.0 dose of vaccine.
   Google Scholar
• Committee for Safety of Medicines. Hepatitis A vaccination (Havrix). CUI7: Prob. Pharmacovigilance 20,16 (1994).
   Google Scholar
• Niu MT, Salive M, Krueger C, Ellenberg SS. Two-year review of hepatitis A vaccine safety: data from the Vaccine Adverse Event Reporting System (VAERS). Gun. Infect. Dis. 26,1475–1476 (1998).
   PubMed Web of Science ®Google Scholar
• Abarca K, Ibanez I, Flores J, Vial PA, Safary A, Potin M. Efficacy of hepatitis A vaccination in children aged 12 to 24 months. Arch. Med. Res. 32,468-472 (2001).
   Google Scholar
• FDC. Reports Pink Sheet. Reports Pink SheetJune(30) (1997).
   Google Scholar
• Beran J, Bentels M, Levie K et al. A single dose, combined vaccine against typhoid fever and hepatitis A: consistency, immunogenicity and reactogenicity. Travel Med. 7,246–252 (2000).
   PubMedGoogle Scholar
• DeFraites RF, Feighner BH, Binn LN et al. Immunization of US soldiers with a two-dose primary series of inactivated hepatitis A vaccine: Early immune response, persistence of antibody and response to a third dose at 1 year. Infect. Dis. 171\(Supp1.1), S61—S69 (1995).
   Google Scholar
• Muller R, Chriske H, Deinhardt F et al. Hepatitis A vaccination: Schedule for accelerated immunization. Vaccine 10\(Suppl. 1), S124—S125 (1992).
   Google Scholar
• Just M, Berger R. Reactogenicity and immunogenicity of inactivated hepatitis A vaccines. Vaccine 10\(Suppl. 1), S110—S113 (1992).
   Google Scholar
• Victor J, Knudsen JD, Nielsen LP et al. Hepatitis A vaccine. A new convenient single-dose schedule with booster when long-term immunization is warranted. Vaccine 12,1327–1329 (1994).
   Google Scholar
• Welty T, Darling K, Magera M et al Hepatitis A vaccination programs in communities with high rates of hepatitis A. MMWR 46, 600–603 (1997).
   Google Scholar